

## References

### I-150

1. Sanchez L, Wang Y, Siegel D, Wang M. Daratumumab: A first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol.* 2016;9(1):51.
2. Naymagon L, Abdul-Hay M. Novel agents in the treatment of multiple myeloma: A review about the future. *J Hematol Oncol.* 2016;9(1):52.
3. Bhatnagar V, Gormley N, Luo L, et al. FDA approval summary: Daratumumab for treatment of multiple myeloma after one prior therapy. 2017;22:1347-1353.
4. Sanchez L, Wang Y, Siegel D, & Wang M. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. *J Hematol Oncol.* 2016;9(1):51.
5. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. *N Engl J Med.* 2016;375:754-766.
6. Mateos M, Dimopoulos M, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. *N Engl J Med.* 2018;378:518-528.
7. Huang H, Zhu J, Yao M, et al. Daratumumab monotherapy for patients with relapsed or refractory natural killer/T-cell lymphoma, nasal type: an open-label, single-arm, multicenter, phase 2 study. *J Hematol Oncol.* 2021;14(1):25.
8. Gordan L, Chang M, Lafeuille M-H, et al. Real-world utilization and safety of daratumumab IV rapid infusions administered in a community setting: A retrospective observational study. *Drugs Real World Outcomes.* 2021;8(2):187-195.
9. Kastritis E, Palladini G, Minnema M, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. *N Engl J Med.* 2021;385(1):46-58.
10. Daratumumab In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated August 8, 2024.
11. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Daratumumab.
12. Clinical Pharmacology™ 2024. Tampa FL: Gold Standard, Inc. Daratumumab hyaluronidase.
13. Micromedex DrugDex Compendium®. 2024. Daratumumab.
14. Micromedex DrugDex Compendium®. 2024. Daratumumab hyaluronidase.
15. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2024.
16. National Comprehensive Cancer Network (NCCN). Daratumumab hyaluronidase. NCCN Drugs and Biologics Compendium®. 2024.

17. Darzalex (daratumumab) injection, for intravenous use [prescribing information]. Janssen Biotech, Inc., Horsham, PA. Revised 07/2024.
18. Darzalex Faspro® (daratumumab and hyaluronidase-fihj) injection, for subcutaneous use [prescribing information]. Janssen Biotech, Inc., Horsham, PA. Revised 7/2024.